Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21409066 | 0.87 | CTSK (0.50) | CTSKCTSSAAK1ATMKMT2A | |
| SCHEMBL31751716 | 0.87 | PPARG (0.48) | CTSKCTSSAAK1CACNA1BATM | |
| SCHEMBL21409069 | 0.87 | CTSK (0.50) | CTSKCTSSAAK1ATMKMT2A | |
| SCHEMBL6832891 | 0.86 | CTSS (0.58) | CTSKCTSSAAK1CACNA1BATM | |
| SCHEMBL14338698 | 0.86 | CTSK (0.59) | CTSKCTSSATMCTSBPPARG | |
| SCHEMBL3842588 | 0.86 | CTSK (0.59) | CTSKCTSSATMCTSBPPARG | |
| SCHEMBL2617332 | 0.86 | CTSS (0.58) | CTSKCTSSAAK1CACNA1BATM | |
| SCHEMBL7696221 | 0.86 | CTSK (0.59) | CTSKCTSSATMCTSBPPARG | |
| SCHEMBL16384160 | 0.85 | PPARA (0.50) | CTSKCTSSATMKMT2ACA2 | |
| SCHEMBL5479821 | 0.84 | CTSK (0.47) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2635560-B1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-8673950-B2 | Dihydrooxazol-2-amine derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673950-B2 | Dihydrooxazol-2-amine derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2635560-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012059371-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-03 | — | — | US | disclosed |
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-03 | — | — | US | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108609-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | TAAR1, TAAR5, HCRTR1 | CTSK 2947/4885CTSS 3667/4885AAK1 699/4885 |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | CTSK 3622/4885CTSS 3650/4885AAK1 873/4885 |
| US-20130345241-A1 | DIHYDROOXAZOL-2-AMINE DERIVATIVES | TAAR1, TAAR5, HCRTR1 | CTSK 2850/4885CTSS 3618/4885AAK1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.